Forge Biologics to Present at Annual Jefferies Global Healthcare Conference

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics, will be presenting at the Jefferies 2022 Global Healthcare Conference on Wednesday, June 8, 2022, 3:00-3:25 p.m. Eastern Time.

“Forge has grown to over 220 employees and we’re excited to share how we are enabling manufacturing success for our gene therapy clients,” said Dr. Miller. “We have made considerable progress expanding to 20 cGMP suites, installed multiple 500L, 1000L, and 5,000L bioreactors for HEK 293 suspension manufacturing, implemented over 20 in-house analytical development assays, and added best-in-class automated fill-finish capabilities to support our expanding client base.”

A live webcast of the presentation can be accessed by visiting Forge’s Events website at https://www.forgebiologics.com/news/#events and will be available for replay for 90 days after the event.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.